Clients like us have to be extra careful, because machinery and worker training in mainland China are generally inferior to those in Hong Kong. We should consider many factors in making this decision: reputation, capacity, quality levels, capability in engineering, the capability of the factories' Chinese suppliers, speed to market, costs, tooling time needed (critical in this project), attention to your company. In the past, due to our small size and limited engineering expertise, we prioritized a close working relationship with the owner of the factory in question. Because the owner took a personal interest in our projects, it reassured us that our needs would be top priority, and he would do whatever it took to produce results. With EChargers, I still strongly believe that this is necessary to ensure we meet the December 7 deadline. A personal relationship is key. What could make that difficult is the fact that the owners of these private toy manufacturers, like many in Hong Kong, all seem to have several businesses going on at once. We are very pressed. We might not have enough time to do proper due diligence on Wai Lung or Wah Shing. We just got these quotes from each of them [see Exhibits II and III]. Although we would like to have more time to qualify more suppliers in the Hong Kong area, we simply can't afford the time. We need engineering development work to start almost immediately

71 1. Is it safe to give piracetam to patients with primary intracerebral haemorrhage? Does it have a neuroprotective effect? 2. Is it safe to give a patient with excessively high blood pressure (as a sequela to recent primary intracerebral haemorrhage) angiotensin-converting enzyme inhibitors to lower the blood pressure? 3. Is it indicated to give piracetam or vincamine to a patient with middle cerebral artery territorial infarction? Do these have any neuroprotective effect?

72 What is the mechanism by which subarachnoid haemorrhage is associated with subhyaloid haemorrhages on fundus examination, and how can cerebrospinal fluid (CSF) gain access to the subhyaloid space inside the eye?

73 What is the recommended dosage for nimodipine given intravenously in cases of subarachnoid haemorrhage, and when should the treatment start? For how long should the dose be continued?

74 I read recently that hyperuricaemia has something to do with stroke? Is it recommended to give allopurinol to stroke patients irrespective of their serum uric acid?

75 Is there a link between hyperuricaemia (although asymptomatic) and atherosclerosis and cerebral ischaemic stroke?

76 Are phenytoin and carbamazepine indicated in myoclonus, occasionally seen in ischemic strokes?

77 What is the treatment of chorea or action myoclonus resulting from embolic stroke to the area of basal ganglia? Does the L-dopa that is given by some neurologists improve the condition? Does valproate have a role if the case is action myoclonus?

78 How should a patient with a haemorrhagic cerebrovascular accident be managed while also having an extensive inferior wall myocardial infarction?

79 What is the best way to manage cortical vein thrombosis? If heparin is to be used, what is the recommended dosage and how long should this treatment last?

80 In the case of cortical vein thrombosis, for how long should anticoagulation be continued?